
Gilead Sciences, Inc.
GILDHealthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18
Clinical Trials (536)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07476339 REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | HIV -1 Infection, HIV (Human Immunodeficiency Virus) | P4 | Recruiting | 200 | Open-label | Bictegravir, emtricitabine, and tenofovir alafenamide |
| NCT07210125 Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting | HIV | P4 | Active | 75 | Open-label | Lenacapavir long-acting |
| NCT06964113 A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice | Ulcerative Colitis | P4 | Active | 94 | Open-label | Filgotinib Maleate |
| NCT05140941 Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy | Hepatitis C, Chronic, Pregnancy; Infection | P4 | Active | 100 | Open-label | Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet |
| NCT06374758 Accelerated ART Initiation for PWHIV Who Are Out of Care | HIV Infections, ART | P4 | Active | 120 | Open-label | bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg |
| NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Triple Negative Breast Cancer | P3 | Recruiting | 1,514 | RCT, Open-label | Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine |
| NCT05814432 Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS | Disseminated Histoplasma Capsulatum Infection, AIDS and Infections | P3 | Recruiting | 279 | RCT, Open-label | Single high dose of liposomal amphotericin B, L-AmB standard dose |
| NCT05502237 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | P3 | Active | 1,021 | RCT, Open-label | Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed |
| NCT06413498 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Multiple Myeloma | P3 | Active | 452 | RCT, Open-label | Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib |
| NCT05552001 Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | Triple Negative Breast Cancer, Metastatic Breast Cancer | P3 | Active | 96 | Open-label | Sacituzumab govitecan |
| NCT03301506 Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) | Primary Biliary Cirrhosis | P3 | Active | 340 | Open-label | Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule |
| NCT05371093 Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | P3 | Active | 231 | RCT, Open-label | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine |
| NCT05382299 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | Triple Negative Breast Cancer, PD-L1 Negative | P3 | Active | 623 | RCT, Open-label | Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin |
| NCT05605899 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | High-risk Large B-cell Lymphoma (LBCL) | P3 | Active | 300 | RCT, Open-label | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone |
| NCT06630299 Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 | HIV-1-Infection | P3 | Active | 600 | RCT, Open-label | ISL/LEN, Antiretroviral Combinations |
| NCT05089734 Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | P3 | Active | 603 | RCT, Open-label | Sacituzumab Govitecan-hziy (SG), Docetaxel |
| NCT07682961 Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy | HIV Infections | P3 | Recruiting | 590 | RCT, Open-label | Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine |
| NCT02881320 Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 | HIV-1 Infection | P2P3 | Active | 177 | Open-label | B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS) |
| NCT05840211 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer | P3 | Active | 654 | RCT, Open-label | Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine |
| NCT06801834 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | P3 | Recruiting | 695 | RCT, Open-label | Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available) |
| NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | Triple Negative Breast Cancer, PD-L1 Positive | P3 | Active | 443 | RCT, Open-label | Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin |
| NCT06486441 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | Endometrial Cancer | P3 | Active | 640 | RCT, Open-label | Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel |
| NCT04595565 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | HER2-negative Breast Cancer, Triple Negative Breast Cancer | P3 | Active | 1,332 | RCT, Open-label | Capecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan |
| NCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | HIV-1-Infection | P2P3 | Active | 675 | RCT, Double-blind | Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC |
| NCT06333808 Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy | HIV-1-infection | P3 | Active | 577 | RCT, Double-blind | Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir |
| NCT05396885 Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Multiple Myeloma | P2 | Active | 136 | Open-label | anitocabtagene-autoleucel |
| NCT04986579 Scalp Cooling in MBC | Metastatic Breast Cancer, Chemotherapy-induced Alopecia | P2 | Recruiting | 120 | Open-label | Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan |
| NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer | Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer | P2 | Active | 192 | RCT, Open-label | Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab |
| NCT05676931 Study With Various Immunotherapy Treatments in Participants With Lung Cancer | Advanced Non-Small Cell Lung Cancer | P2 | Active | 400 | RCT, Open-label | Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet |
| NCT06048133 Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | Biliary Tract Carcinoma, Cholangiocarcinoma | P2 | Active | 33 | Open-label | Gemcitabine, Cisplatin, Zimberelimab, Quemliclustat |
| NCT05327530 A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | Locally Advanced or Metastatic Urothelial Carcinoma | P2 | Active | 256 | RCT, Open-label | Avelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100 |
| NCT06727565 Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | Head and Neck Squamous Cell Carcinoma | P2 | Active | 39 | RCT, Open-label | Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin |
| NCT06657222 First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Advanced Solid Tumors, HNSCC | P1P2 | Recruiting | 250 | RCT, Open-label | TUB-030 |
| NCT03971409 Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Stage III Breast Cancer, Stage IIIA Breast Cancer | P2 | Active | 145 | RCT, Open-label | Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab, Liposomal Doxorubicin, Sacituzumab Govitecan |
| NCT06477419 A Study of Sacituzumab Govitecan in People With Mesothelioma | Mesothelioma, Mesotheliomas Pleural | P2 | Recruiting | 33 | Open-label | Sacituzumab govitecan-hziy |
| NCT06248515 A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Thymoma, Thymic Carcinoma | P2 | Recruiting | 18 | Open-label | Sacituzumab govitecan-hziy |
| NCT07736937 Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | Ovarian Cancer | P1P2 | Recruiting | 72 | Open-label | TUB-040 + Carbo + BEV |
| NCT07841977 Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis | Primary Biliary Cholangitis | P2 | Recruiting | 132 | RCT, Double-blind | Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A |
| NCT05884320 Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | Gland, Salivary Gland Cancers | P2 | Active | 63 | RCT, Open-label | Sacituzumab Govitecan |
| NCT06923826 Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) | Salivary Gland Cancer, Thyroid Cancer | P2 | Recruiting | 32 | Open-label | Sacituzumab govitecan |
| NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P2 | Active | 176 | RCT, Double-blind | Tilpisertib Fosmecarbil, Placebo |
| NCT06401824 Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | NSCLC Stage IV, Brain Metastases, Adult | P2 | Recruiting | 25 | Open-label | Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab |
| NCT03547973 Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Metastatic Urothelial Cancer | P2 | Active | 502 | Open-label | Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin |
| NCT04989803 Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | Relapsed and/or Refractory B-cell Lymphoma | P1P2 | Active | 247 | Open-label | Cyclophosphamide, Fludarabine, KITE-363, KITE-753 |
| NCT06238921 Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | Breast Cancer, Triple Negative Breast Cancer | P1P2 | Recruiting | 31 | Open-label | Zimberelimab, Sacituzumab govitecan |
| NCT06303505 FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | Ovarian Cancer, Non-small Cell Lung Cancer | P1P2 | Recruiting | 334 | Open-label | TUB-040, Bevacizumab |
| NCT06612203 Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer | Advanced Breast Cancer | P1P2 | Active | 76 | Open-label | Debio 0123 and Sacituzumab govitecan |
| NCT05186974 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | P2 | Active | 193 | RCT, Open-label | Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin |
| NCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P2 | Active | 150 | RCT, Double-blind | TAF, Placebo |
| NCT04448886 Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Invasive Breast Cancer, Metastatic Breast Cancer | P2 | Active | 110 | RCT, Open-label | Pembrolizumab, Sacituzumab Govitecan |
| NCT07546812 Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas | HER2-negative, Gastroesophageal Junction | P2 | Recruiting | 120 | RCT, Open-label | Denikitug, Nivolumab, Ramucirumab, Paclitaxel |
| NCT06665178 Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | Breast Cancer | P2 | Recruiting | 20 | Open-label | Sacituzumab Govitecan |
| NCT07645287 A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | HIV-1-infection | P2 | Recruiting | 175 | RCT, Open-label | GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF |
| NCT05457010 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | P1 | Active | 24 | Open-label | SPRX002, ARC-T Cells, Cyclophosphamide, Fludarabine |
| NCT05833867 Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer | Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | P1 | Recruiting | 20 | Open-label | Sacituzumab govitecan |
| NCT04155749 Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P1 | Active | 40 | Open-label | anitocabtagene-autoleucel |
| NCT06167317 Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Recruiting | 278 | Open-label | GS-0201, Sacituzumab Govitecan |
| NCT07128303 Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 476 | Open-label | GS-5319, Carboplatin, Pemetrexed, Pembrolizumab |
| NCT06065371 Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Gastrointestinal Cancer | P1 | Recruiting | 20 | Open-label | Capecitabine, Sacituzumab govetican |
| NCT05840224 Study of GS-4528 in Adults With Solid Tumors | Solid Tumor | P1 | Active | 182 | Open-label | GS-4528, Zimberelimab |
| NCT06082960 Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | Solid Tumors | P1 | Active | 45 | Open-label | GS-9911, Zimberelimab |
| NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | HIV Infections, Hepatitis B | Recruiting | 24,258 | — | — | |
| NCT03275311 Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | Metastatic Breast Cancer | Recruiting | 42,000 | — | — | |
| NCT03577197 Southeast Netherlands Advanced Metastatic Breast Cancer Registry | Advanced Breast Cancer, Metastatic Breast Cancer | Recruiting | 7,000 | — | — | |
| NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic | Recruiting | 14,500 | — | — | |
| NCT07652359 Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care | Shared Decision-Making, Quality of Life | N/A | Recruiting | 138 | RCT, Double-blind | — |
| NCT06889805 HDV Screening Study | Hepatitis D Virus Infection | Recruiting | 300 | — | — | |
| NCT04956445 Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development | Covid19 | Recruiting | 2,000 | — | — | |
| NCT07238114 Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors | Liver Cirrhosis, Viral Pneumonia | Active | 450 | — | — | |
| NCT06774027 Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer | HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma | Recruiting | 100 | — | Non-Investigational Antibody-Drug Conjugates (ADC) | |
| NCT07473778 Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention | HIV Infections | Recruiting | 3,000 | — | Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet | |
| NCT05688592 Usefulness of PET-CT for Invasive Fungal Infection | Invasive Fungal Infections | Recruiting | 224 | — | — | |
| NCT01961232 Trans-pulmonary Biomarkers in Pulmonary Hypertension | Pulmonary Hypertension | Active | 100 | — | — | |
| NCT06353295 Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study | HIV/AIDS | N/A | Active | 140 | Open-label | — |
| NCT03502005 Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 | Human Immunodeficiency Virus | P4 | Completed | 100 | Open-label | bictegravir/emtricitabine/tenofovir alafenamide |
| NCT02691728 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease | Chronic Hepatitis C | P4 | Unknown | 40 | Open-label | LDV/SOF FDC |
| NCT03044964 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR) | Angina | P4 | Unknown | 40 | RCT, Double-blind | Ranolazine, Placebo |
| NCT01641367 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure | HIV-1 Infection | P4 | Completed | 545 | RCT, Open-label | Darunavir, Etravirine, Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs), Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available |
| NCT02800655 Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy | HIV | P4 | Unknown | 100 | Open-label | — |
| NCT04650269 Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program | Harm Reduction, HIV Infections | P4 | Completed | 27 | Open-label | Biktarvy 50Mg-200Mg-25Mg Tablet |
| NCT03717129 Analysis of Crushed and Whole Tablet Genvoya | Healthy Volunteers | P4 | Completed | 12 | Open-label | Genvoya Oral dose, Genvoya Crushed Dose |
| NCT00389402 BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes | HIV Infections | P4 | Completed | 120 | RCT, Open-label | saquinavir/ritonavir, atazanavir/ritonavir |
| NCT03309592 Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension | Portopulmonary Hypertension, Pulmonary Hypertension | P4 | Withdrawn | — | Open-label | Ambrisentan Pill, Tadalafil Pill |
| NCT00697944 Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients | Sepsis, Candida | P4 | Unknown | 30 | Open-label | Amphotericine in liposome (Ambisome®) |
| NCT03549312 Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy | HIV-1-infection, Hepatitis C, Chronic | P4 | Unknown | 25 | Open-label | Genvoya, Epclusa, Biktarvy |
| NCT01448616 Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding | Herpes Simplex Type II | P4 | Completed | 73 | RCT, Double-blind | TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets |
| NCT00724711 Safety and Efficacy Study of Switching From Epzicom to Truvada | HIV Infection | P4 | Completed | 312 | RCT, Open-label | emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC) |
| NCT00224458 Combination of Efavirenz and Truvada - COMET Study | HIV Infections | P4 | Completed | 400 | Open-label | Truvada, efavirenz |
| NCT00644332 An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041) | Chronic Angina | P4 | Completed | 172 | Open-label | Ranolazine |
| NCT04538040 Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine | HIV-1-infection | P4 | Completed | 20 | Open-label | Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch |
| NCT04551573 A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects | Tuberculosis, Hiv | P4 | Withdrawn | — | RCT, Open-label | Rifapentine daily, Rifapentine weekly |
| NCT01334203 A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM) | Angina Pectoris, Coronary Artery Disease | P4 | Withdrawn | — | RCT, Double-blind | Ranolazine |
| NCT00444379 Anti-Retrovirals for Kaposi's Sarcoma | Kaposi's Sarcoma, HIV Infections | P4 | Completed | 224 | RCT, Single-blind | Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir |
| NCT01338636 An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) | Exercise-induced Pulmonary Arterial Hypertension | P4 | Completed | 30 | Open-label | Ambrisentan |
| NCT03696290 Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis | Bronchiectasis Adult | P4 | Terminated | 34 | RCT, Double-blind | Aztreonam lysine |
| NCT03032666 Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial | Thalassemia, Hepatitis C | P4 | Completed | 7 | Open-label | sofosbuvir/velpatasvir |
| NCT01522625 Tenofovir in Chronic Hepatitis B With Mild ALT Elevation | Chronic Hepatitis B | P4 | Completed | 160 | RCT, Double-blind | tenofovir disoproxil fumarate 300mg per day, Placebo |
| NCT05147740 Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age | HIV-1-infection | P4 | Unknown | 50 | Open-label | B/F/TAF |
| NCT00775606 Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease | Acquired Immune Deficiency Syndrome | P4 | Terminated | 15 | RCT, Open-label | Lopinavir 400 mg/ritonavir 100 mg, Efavirenz |
| NCT00224445 Boosted Atazanavir and Truvada Given Once-Daily - BATON Study | HIV Infections | P4 | Completed | 100 | Open-label | Truvada, Atazanavir, Ritonavir |
| NCT06830668 Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation | HIV Infection, HIV | P4 | Not Yet Recruiting | 250 | Open-label | Regimen:BIC+FTC+TAF |
| NCT01214759 Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) | HIV | P4 | Completed | 103 | Open-label | Truvada, Raltegravir |
| NCT02283060 Sleep and Cognition After Atripla to Stribild Switch | HIV | P4 | Unknown | 30 | RCT, Open-label | Stribild, Atripla |
| NCT02128542 Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis | Hepatitis C Virus Infection | P4 | Completed | 66 | Open-label | Sofosbuvir, RBV |
| NCT00840463 Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan | Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | P4 | Terminated | 4 | RCT, Double-blind | Ambrisentan |
| NCT07560046 Combating Related Epidemics in HCV | HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | P4 | Not Yet Recruiting | 1,280 | RCT, Open-label | Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] |
| NCT02829034 Targeting Right Ventricle in Pulmonary Hypertension Gilead | Pulmonary Hypertension | P4 | Completed | 22 | RCT, Double-blind | Ranolazine, Placebo |
| NCT02052011 Ranolazine and Microvascular Angina by PET in the Emergency Department | Microvascular Angina | P4 | Completed | 31 | RCT, Double-blind | Ranolazine, Placebo |
| NCT04965662 The Role of Home Packs of HIV PEPSE in High Risk Individuals | HIV-1-infection | P4 | Completed | 139 | RCT, Open-label | Maraviroc, Truvada |
| NCT01051960 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan | Systemic Sclerosis, Shortness of Breath | P4 | Completed | 12 | Open-label | Ambrisentan |
| NCT04944654 Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH | Human Immunodeficiency Virus | P4 | Terminated | 1 | Open-label | BIKTARVY 50Mg-200Mg-25Mg Tablet |
| NCT04530630 Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant | HIV Infections, Renal Transplant Rejection | P4 | Completed | 20 | Open-label | BIC/F/TAF 50Mg-200Mg-25Mg Tablet |
| NCT00386997 ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia | Fungal Infection | P4 | Terminated | 20 | Open-label | liposomal amphotericin B (AmBisome®) |
| NCT02529059 SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms | HIV | P4 | Completed | 40 | Open-label | Eviplera |
| NCT00365612 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients | HIV Infections | P4 | Completed | 300 | RCT, Open-label | Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) |
| NCT02957864 Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide | Renal Insufficiency,Chronic, Hiv | P4 | Unknown | 80 | RCT, Open-label | tenofovir alafenamide, abacavir |
| NCT02246998 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults | HIV-1 Infection | P4 | Completed | 72 | RCT, Open-label | STB, TVD, ATR, RTV, ATV, ABC/3TC, Iohexol |
| NCT02253394 The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study | Pulmonary Arterial Hypertension | P4 | Terminated | 2 | RCT, Double-blind | Ambrisentan plus Spironolactone, Ambrisentan plus Placebo |
| NCT00230477 Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT | Hepatitis B | P4 | Completed | 19 | RCT, Open-label | Hepsera, Hepsera and lamivudine |
| NCT03987503 The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study | Hepatitis C, Chronic | P4 | Completed | 87 | Open-label | Epclusa (SOF/VEL), Standard of care |
| NCT02149888 PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 | HIV, Human Immunodeficiency Virus | P4 | Completed | 52 | Open-label | Tenofovir/emtricitabine |
| NCT00670657 CRITIC - Treatment of Candidemia and Invasive Candidiasis | Candidemia, Invasive Candidiasis | P4 | Completed | 39 | Open-label | AmBisome |
| NCT05528653 Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP" | HIV Prevention | P4 | Completed | 75 | Open-label | Descovy |
| NCT00832572 Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy | Coronary Artery Disease, Pain | P4 | Terminated | 5 | RCT, Double-blind | Ranolazine, Placebo |
| NCT03471624 Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) | Hepatitis B, Chronic | P4 | Completed | 270 | Open-label | Tenofovir Alafenamide |
| NCT02133352 Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction | Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction | P4 | Completed | 10 | Open-label | Ranolazine |
| NCT03532425 B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults | HIV-1-infection | P4 | Terminated | 28 | RCT, Double-blind | B/F/TAF, Atripla, B/F/TAF Placebo, Atripla Placebo |
| NCT00615745 ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla | HIV Infections | P4 | Completed | 115 | Open-label | Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg |
| NCT00389194 PREventing Progression of Adipose Tissue Redistribution | HIV Infections | P4 | Completed | 120 | RCT, Open-label | continuing AZT+3TC or switching AZT+3TC to TDF+ FTC |
| NCT05243602 BFTAF Elderly Switch Study | HIV-1-infection | P4 | Completed | 520 | RCT, Open-label | Switch to B/F/TAF, Continue current regimen |
| NCT03350672 Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide | Hiv | P4 | Completed | 37 | Open-label | FTC/TAF |
| NCT00192595 Tenofovir in HIV/HBV Coinfection | HIV Infection, Hepatitis B Coinfection | P4 | Completed | 36 | RCT, Open-label | Tenofovir, Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV) |
| NCT02739360 Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 | Lymphoid Malignancies | P4 | Terminated | 3 | Open-label | Idelalisib |
| NCT07908446 Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV | HIV-1 Infection | P4 | Not Yet Recruiting | 400 | RCT, Open-label | BIC/LEN FDC, Lenacapavir, SBR |
| NCT01761643 CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM | Patient Adherence, HIV Seronegativity | P4 | Completed | 398 | RCT, Open-label | — |
| NCT06525389 Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) | Talaromycosis | P3 | Not Yet Recruiting | 428 | RCT, Double-blind | Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB) |
| NCT02344290 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults | HIV, Cardiovascular Diseases | P3 | Completed | 7,769 | RCT, Double-blind | Pitavastatin, Placebo |
| NCT04843761 ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 | Covid19 | P3 | Completed | 473 | RCT, Double-blind | Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid |
| NCT00208299 ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | Coronary Artery Disease | P3 | Completed | 1,231 | RCT, Double-blind | Regadenoson, Adenosine |
| NCT00208312 ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | Coronary Artery Disease | P3 | Completed | 787 | RCT, Double-blind | Regadenoson, Adenosine |
| NCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | Advanced Upper Gastrointestinal Tract Adenocarcinoma | P3 | Completed | 1,040 | RCT, Open-label | Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab |
| NCT00757237 Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa | Cystic Fibrosis | P3 | Completed | 274 | RCT, Open-label | Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS) |
| NCT01872988 Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma | Chronic Hepatitis B, Hepatocellular Carcinoma | P3 | Terminated | 320 | RCT, Double-blind | Tenofovir, Placebo |
| NCT00823342 ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy | HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection | P3 | Terminated | 150 | RCT, Double-blind | CLEVUDINE + TENOFOVIR PLACEBO, CLEVUDINE IN ASSOCIATION TENOFOVIR, TENOFOVIR + CLEVUDINE PLACEBO |
| NCT03852719 Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) | Chronic Hepatitis Delta | P3 | Completed | 150 | RCT, Open-label | Bulevirtide |
| NCT00071201 Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B | Chronic Hepatitis B | P3 | Completed | 48 | Open-label | Adefovir Dipivoxil for oral suspension, 2 mg/mL |
| NCT06060665 Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) | Primary Biliary Cholangitis | P3 | Completed | 96 | RCT, Double-blind | Seladelpar 10 mg, Placebo |
| NCT01313624 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | Bronchiectasis | P3 | Completed | 266 | RCT, Double-blind | AZLI, Placebo |
| NCT03901339 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | P3 | Completed | 543 | RCT, Open-label | Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine |
| NCT01854775 Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | P2P3 | Completed | 129 | Open-label | E/C/F/TAF, E/C/F/TAF (Low Dose) |
| NCT01095796 Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV, HIV Infections | P3 | Completed | 707 | RCT, Double-blind | Stribild, Atripla, Stribild Placebo, Atripla Placebo |
| NCT01967940 Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults | HIV, HIV Infections | P3 | Completed | 55 | RCT, Double-blind | TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV |
| NCT03547908 Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults | HIV-1/HBV Co-Infection | P3 | Completed | 244 | RCT, Double-blind | B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF |
| NCT02889796 Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate | Rheumatoid Arthritis | P3 | Completed | 1,759 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX |
| NCT01108510 Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | HIV, HIV Infections | P3 | Completed | 698 | RCT, Double-blind | COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo |
| NCT00528957 Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children | HIV Infections | P3 | Completed | 97 | RCT, Open-label | Tenofovir DF, Zidovudine, Stavudine |
| NCT01033760 Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) | HIV-1 Infections | P3 | Completed | 90 | RCT, Open-label | raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine, darunavir; ritonavir; emtricitabine/tenofovir |
| NCT01314716 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | Bronchiectasis | P3 | Completed | 274 | RCT, Double-blind | AZLI, Placebo |
| NCT02480712 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection | Hepatitis C Virus Infection | P3 | Completed | 107 | Open-label | SOF/VEL |
| NCT04745351 Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) | COVID-19 | P3 | Terminated | 249 | RCT, Double-blind | Remdesivir, RDV Placebo, Standard of Care |
| NCT04313881 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndromes | P3 | Terminated | 539 | RCT, Double-blind | Magrolimab, Azacitidine, Placebo |
| NCT01352416 Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery | Heart; Dysfunction Postoperative, Cardiac Surgery | P3 | Terminated | 15 | RCT, Double-blind | Ranolazine, Placebo |
| NCT02300558 Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 | Long QT Syndrome Type 3 | P3 | Terminated | 41 | Single-blind | Eleclazine, Eleclazine placebo |
| NCT01838590 Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection | Hepatitis C Virus | P3 | Completed | 103 | RCT, Open-label | SOF, RBV |
| NCT02616783 Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years | HIV-1 Infection | P3 | Completed | 167 | RCT, Open-label | E/C/F/TAF, TDF, FTC, FTC/TDF, 3TC, Third agent |
| NCT02616029 Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I | HIV-1 Infection | P3 | Completed | 66 | RCT, Open-label | E/C/F/TAF |
| NCT01682720 Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection | Hepatitis C | P3 | Completed | 421 | RCT, Double-blind | SOF, RBV, Placebo to match SOF, Placebo to match RBV |
| NCT02671500 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV | Hepatitis C Virus Infection | P3 | Completed | 375 | Open-label | SOF/VEL |
| NCT00323544 SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection | HIV Infections | P3 | Completed | 220 | RCT, Open-label | zidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF |
| NCT04292899 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | COVID-19 | P3 | Completed | 4,891 | RCT, Open-label | Remdesivir, Standard of Care |
| NCT01667731 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults | Hepatitis C, Human Immunodeficiency Virus | P3 | Completed | 224 | Open-label | SOF, RBV |
| NCT02600819 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis | HIV-1 Infection | P3 | Completed | 55 | Open-label | E/C/F/TAF, B/F/TAF |
| NCT01363011 Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment | Acquired Immunodeficiency Syndrome, HIV Infections | P3 | Completed | 106 | Open-label | E/C/F/TDF, COBI, ATV, DRV, NRTI |
| NCT00777920 Study of Ambrisentan in Participants With Pulmonary Hypertension | Pulmonary Hypertension | P3 | Completed | 140 | Open-label | Ambrisentan |
| NCT01691768 Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services | HIV | P2P3 | Completed | 372 | RCT, Open-label | 1% tenofovir gel |
| NCT02472886 Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 153 | Open-label | LDV/SOF, RBV |
| NCT02660905 HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection | Human Immunodeficiency Virus, Hepatitis C, Chronic | P3 | Completed | 25 | Open-label | E/C/F/TAF;, Ledipasvir-Sofosbuvir |
| NCT04527991 Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Locally Advanced or Metastatic Unresectable Urothelial Cancer | P3 | Completed | 711 | RCT, Open-label | Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine |
| NCT00158821 Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. | HIV Infections | P3 | Completed | 180 | Open-label | Viread (tenofovir disoproxil fumarate), Sustiva (Efavirenz), Epivir (Lamivudine), Zerit (Stavudine) Placebo |
| NCT00353574 DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension | Hypertension | P3 | Terminated | 282 | RCT, Double-blind | Darusentan |
| NCT01252940 Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF | HIV-1 Infection | P3 | Completed | 482 | RCT, Open-label | FTC/RPV/TDF, PI, RTV, NRTIs |
| NCT01701401 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV | Chronic Hepatitis C Virus | P3 | Completed | 870 | RCT, Open-label | LDV/SOF, RBV |
| NCT05090410 Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate | Rheumatoid Arthritis, JAK Inhibitor | P3 | Unknown | 400 | RCT, Open-label | filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly |
| NCT04409262 A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | COVID-19 Pneumonia | P3 | Completed | 649 | RCT, Double-blind | Remdesivir, Tocilizumab, Placebo |
| NCT02738333 Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 239 | RCT, Open-label | LDV/SOF, SOF, RBV |
| NCT01910636 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection | Hepatitis C | P3 | Completed | 153 | Open-label | Sofosbuvir, RBV |
| NCT01174173 Ranolazine and Pulmonary Hypertension | Angina, Pulmonary Arterial Hypertension | P3 | Completed | 11 | Open-label | Ranolazine |
| NCT03696160 The Late Presenter Treatment Optimisation Study | HIV/AIDS | P3 | Completed | 447 | RCT, Open-label | Biktarvy, Symtuza |
| NCT00104520 Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa | Cystic Fibrosis | P3 | Completed | 211 | RCT, Double-blind | AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID) |
| NCT01896193 Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection | Hepatitis C | P3 | Completed | 127 | RCT, Open-label | SOF, RBV |
| NCT01980875 Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P3 | Terminated | 57 | RCT, Open-label | Idelalisib, Chlorambucil, Obinutuzumab |
| NCT02842086 Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection | Pre-Exposure Prophylaxis of HIV-1 Infection | P3 | Terminated | 5,399 | RCT, Double-blind | F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo |
| NCT04112303 Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis | Hepatitis C Virus Infection | P3 | Completed | 37 | Open-label | SOF/VEL |
| NCT01539512 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P3 | Completed | 220 | RCT, Double-blind | Idelalisib, Rituximab, Placebo to match idelalisib |
| NCT02201901 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis | Hepatitis C Virus Infection | P3 | Completed | 268 | RCT, Open-label | SOF/VEL, RBV |
| NCT00091429 Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine | Angina | P3 | Completed | 500 | RCT, Double-blind | Ranolazine |
| NCT01768286 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection | Chronic Hepatitis C Virus | P3 | Completed | 441 | RCT, Open-label | LDV/SOF, RBV |
| NCT00712166 Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa | Cystic Fibrosis, Lung Infection | P3 | Completed | 160 | RCT, Double-blind | AZLI 75 mg three times daily (TID), Placebo three times daily (TID) |
| NCT02825212 Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia | Hepatitis C, Cryoglobulinemia | P2P3 | Completed | 10 | Open-label | Harvoni, Epclusa |
| NCT02603120 Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed | HIV-1 Infection | P3 | Completed | 567 | RCT, Double-blind | ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo |
| NCT07178730 NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer | Breast Cancer, Triple-negative Breast Cancer | P3 | Not Yet Recruiting | 765 | RCT, Open-label | Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy |
| NCT00111150 Botswana Tenofovir Oral HIV Prophylaxis Trial | HIV Infection | P2P3 | Terminated | 1,200 | RCT, Double-blind | Tenofovir Disoproxil Fumarate 300 mg daily |
| NCT03110380 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed | HIV-1-infection | P3 | Completed | 567 | RCT, Double-blind | B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo |
| NCT01815736 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants | HIV, HIV Infections | P3 | Completed | 1,443 | RCT, Open-label | E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI |
| NCT01259713 Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia | Invasive Fungal Disease | P3 | Completed | 355 | RCT, Double-blind | Liposomal amphotericin B, Placebo |
| NCT04653194 Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' | Human Immunodeficiency Virus | P3 | Completed | 36 | RCT, Open-label | Biktarvy, Symtuza |
| NCT01818596 Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment | HIV, HIV Infections | P3 | Completed | 252 | Open-label | E/C/F/TAF |
| NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Completed | 2,731 | RCT, Open-label | Filgotinib, Placebo to match filgotinib |
| NCT01641822 Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF | Cystic Fibrosis | P3 | Completed | 107 | RCT, Double-blind | AZLI, Placebo to match AZLI, Tobramycin inhalation solution |
| NCT02469246 Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC | HIV-1 Infection | P3 | Completed | 567 | RCT, Double-blind | F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent |
| NCT01106586 Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV, HIV Infections | P3 | Completed | 708 | RCT, Double-blind | Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo |
| NCT01732913 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Indolent Non-Hodgkin's Lymphomas | P3 | Terminated | 295 | RCT, Double-blind | Placebo, Rituximab, Idelalisib |
| NCT01542788 Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon | Chronic Hepatitis C | P3 | Completed | 278 | RCT, Double-blind | SOF, RBV, Placebo to match SOF, Placebo to match RBV |
| NCT00811954 Comparative Study of Three NNRTI-Sparing HAART Regimens | HIV Infection | P3 | Completed | 1,814 | RCT, Open-label | Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir |
| NCT00928187 Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) | HIV, HIV Infections | P3 | Completed | 454 | RCT, Open-label | emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation) |
| NCT01732926 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Indolent Non-Hodgkin's Lymphomas | P3 | Terminated | 475 | RCT, Double-blind | Idelalisib, Rituximab, Bendamustine, Placebo |
| NCT00578786 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) | Pulmonary Arterial Hypertension | P3 | Completed | 383 | RCT, Double-blind | ambrisentan |
| NCT03631732 Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants | HIV-1 Infection | P3 | Completed | 496 | RCT, Open-label | B/F/TAF, NRTIs, Third Agent |
| NCT02886728 Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy | Rheumatoid Arthritis | P3 | Completed | 1,252 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX |
| NCT02639338 Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis | Hepatitis C Virus Infection | P3 | Completed | 220 | RCT, Open-label | SOF/VEL/VOX, SOF/VEL |
| NCT05715528 Study of Obeldesivir in Nonhospitalized Participants With COVID-19 | COVID-19 | P3 | Completed | 2,011 | RCT, Double-blind | Obeldesivir, Obeldesivir Placebo |
| NCT04115839 Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy | Psoriatic Arthritis | P3 | Terminated | 106 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib |
| NCT01940341 Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen | HBeAg-negative Chronic Hepatitis B | P3 | Completed | 426 | RCT, Double-blind | TAF, TDF, TAF Placebo, TDF Placebo |
| NCT00495651 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) | HIV Infections, Tuberculosis | P3 | Completed | 2,073 | RCT, Open-label | Antiretroviral medications, Antiretroviral medications+Isoniazid prophylaxis, Antiretroviral medications, Antiretroviral medications+Isoniazid prophylaxis |
| NCT02597166 Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection | Hepatitis C, Chronic, Cirrhosis, Decompensated | P3 | Completed | 14 | Open-label | Ledipasvir/Sofosbuvir |
| NCT07887672 A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma | Newly Diagnosed Multiple Myeloma | P3 | Not Yet Recruiting | 600 | RCT, Open-label | Anitocabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Fludarabine, Cyclophosphamide |
| NCT02605954 Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults | HIV-1 Infection | P3 | Completed | 275 | RCT, Open-label | E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent |
| NCT02487030 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 255 | RCT, Open-label | LDV/SOF, RBV |
| NCT05079230 Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | Acute Myeloid Leukemia | P3 | Terminated | 378 | RCT, Double-blind | Magrolimab, Venetoclax, Azacitidine, Placebo |
| NCT00158730 Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment | Invasive Aspergillosis, Other Fungal Infections | P3 | Completed | 800 | RCT, Double-blind | AmBisome |
| NCT00423748 Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. | Pulmonary Arterial Hypertension | P3 | Completed | 186 | RCT, Double-blind | ambrisentan |
| NCT02545504 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Adenocarcinoma | P3 | Completed | 432 | RCT, Double-blind | Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin |
| NCT00051285 ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure" | Heart Failure, Congestive | P3 | Terminated | 1,800 | RCT, Double-blind | Enoximone, Enoximone placebo |
| NCT01442038 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) | Coronary Artery Disease, Angina Pectoris | P3 | Completed | 2,651 | RCT, Double-blind | Ranolazine, Placebo |
| NCT00003338 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | Lymphoma | P2P3 | Unknown | 60 | — | — |
| NCT02104700 Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir | HIV | P2P3 | Completed | 150 | RCT, Open-label | Rilpivirine/Emtricitabine/Tenofovir |
| NCT01956812 Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer, Pancreatic Cancer | P3 | Terminated | 334 | RCT, Double-blind | IMMU-107, placebo, Gemcitabine |
| NCT01968551 Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults | HIV-1, HIV Infections | P3 | Completed | 158 | RCT, Open-label | E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen |
| NCT04742491 Pre-Exposure Prophylaxis for Transgender Women in the US and South America | HIV Prevention | P2P3 | Completed | 304 | RCT, Open-label | Immediate Intervention Arm, Deferred Intervention Arm |
| NCT03602560 ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | Primary Biliary Cholangitis | P3 | Completed | 265 | RCT, Double-blind | seladelpar 5-10 mg, seladelpar 10 mg, Placebo |
| NCT07658976 Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy | HIV Infection, Sexually Transmitted Infection | P3 | Not Yet Recruiting | 400 | RCT, Open-label | HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP |
| NCT03512418 Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) | HIV Infections, Substance Use Disorders | P3 | Completed | 30 | RCT, Open-label | Truvada |
| NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | P2 | Completed | 169 | RCT, Open-label | Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab |
| NCT03869190 Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | Urothelial Carcinoma, Bladder Cancer | P1P2 | Terminated | 272 | RCT, Open-label | Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine |
| NCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | P1P2 | Completed | 173 | RCT, Open-label | Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG |
| NCT05329766 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | Gastrointestinal Tract Malignancies | P2 | Completed | 332 | RCT, Open-label | Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin |
| NCT00419770 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study | Mucormycosis | P2 | Completed | 20 | RCT, Double-blind | deferasirox, Placebo, Liposomal amphotericin B |
| NCT04891770 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | Chronic Hepatitis B | P2 | Completed | 103 | RCT, Open-label | Tenofovir Alafenamide, VIR-2218, Nivolumab, Selgantolimod |
| NCT02745535 Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience | Chronic Hepatitis C | P2 | Completed | 77 | Open-label | Sofosbuvir/Velpatasvir/Voxilaprevir |
| NCT04262856 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | P2 | Completed | 151 | RCT, Open-label | Domvanalimab, Etrumadenant, Zimberelimab |
| NCT03074786 Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH) | HIV-1-infection | P2 | Withdrawn | — | RCT, Open-label | Dapivirine, Truvada |
| NCT01887353 The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure | Atrial Fibrillation, Heart Failure | P2 | Terminated | 8 | RCT, Double-blind | Ranolazine, Placebo |
| NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Metastatic Colorectal Cancer | P1P2 | Completed | 227 | RCT, Single-blind | AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib |
| NCT01067443 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa | Primary Visceral Leishmaniasis | P2 | Completed | 151 | RCT, Open-label | Liposomal amphotericin B (AmBisome®) and sodium stibogluconate, Liposomal amphotericin B + miltefosine, Miltefosine |
| NCT01055847 Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection | Cystic Fibrosis, CF | P2 | Completed | 105 | RCT, Double-blind | Aztreonam for Inhalation (AI), Placebo |
| NCT03434353 Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | P2 | Terminated | 123 | RCT, Open-label | Inarigivir Soproxil, TAF |
| NCT06631365 PrEPsmart 2-1-1 Pilot | HIV-1-infection | P2 | Unknown | 60 | RCT, Open-label | Truvada |
| NCT02926833 Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B Cell Lymphoma | P1P2 | Completed | 37 | Open-label | KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine |
| NCT01435044 Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection | Hepatitis C, Chronic | P2 | Completed | 239 | RCT, Double-blind | Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938 |
| NCT02300103 Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study | Hepatitis C Virus Infection | P2 | Completed | 69 | Open-label | SOF/VEL, RBV |
| NCT02258529 Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | Follicular Lymphoma, Small Lymphocytic Lymphoma | P2 | Terminated | 10 | Open-label | Idelalisib, Rituximab |
| NCT04130919 Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P2 | Terminated | 19 | RCT, Double-blind | Tilpisertib, Placebo |
| NCT01054729 Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients | Hepatitis C | P2 | Completed | 64 | RCT, Double-blind | Sofosbuvir, Placebo, PEG, RBV |
| NCT02249182 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection | Hepatitis C Virus Infection | P2 | Completed | 226 | Open-label | LDV/SOF, RBV |
| NCT03046056 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) | Small Bowel Crohn's Disease | P2 | Completed | 78 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib |
| NCT04364035 Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients | HIV/AIDS | P2 | Completed | 50 | RCT, Double-blind | ChAdOx1.HTI, MVA.HTI, GS-9620, Placebo, Placebo Oral Tablet |
| NCT00423592 Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension | Pulmonary Hypertension | P2 | Completed | 36 | Open-label | ambrisentan |
| NCT01334567 Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan | Hepatitis B | P2 | Completed | 30 | Open-label | Tenofovir DF |
| NCT02405442 Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | P2 | Terminated | 187 | RCT, Double-blind | Andecaliximab, Placebo |
| NCT01858766 Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection | Hepatitis C | P2 | Completed | 379 | RCT, Open-label | SOF, VEL, RBV |
| NCT01730612 ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA | HER2 Negative Breast Carcinoma Expressing CEA | P1P2 | Completed | 23 | Open-label | TF2 - 68 Ga-IMP-288: |
| NCT01687257 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation | Hepatitis C, Cirrhosis | P2 | Completed | 50 | RCT, Open-label | SOF, RBV |
| NCT02536313 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen | Hepatitis C Virus Infection | P2 | Completed | 49 | RCT, Open-label | SOF/VEL/VOX, RBV |
| NCT01225380 A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | Chronic Hepatitis C Infection | P2 | Completed | 324 | RCT, Double-blind | GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo, Pegasys®, Copegus® |
| NCT02301936 Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease | Hepatitis C Virus Infection | P2 | Completed | 10 | Open-label | LDV/SOF |
| NCT06682234 Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease | Filovirus Disease, Postexposure Prophylaxis for Filovirus Disease | P2 | Withdrawn | — | Open-label | obeldesivir |
| NCT01369498 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | Myelofibrosis | P2 | Completed | 54 | RCT, Open-label | Simtuzumab, Ruxolitinib |
| NCT02254421 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract | Respiratory Syncytial Virus Infection | P2 | Completed | 60 | RCT, Double-blind | Presatovir, Placebo |
| NCT00832507 Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P2 | Terminated | 162 | RCT, Double-blind | Cicletanine, Cicletanine Placebo |
| NCT02968563 Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P2 | Completed | 35 | Open-label | Tirabrutinib, Idelalisib, Obinutuzumab |
| NCT00421525 Phase I/II Study of hLL1 in Multiple Myeloma | Multiple Myeloma, Myeloma, Plasma-Cell | P1P2 | Completed | 25 | Open-label | milatuzumab |
| NCT02219685 Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection | Hepatitis C Virus Infection | P2 | Completed | 40 | RCT, Double-blind | LDV/SOF, Placebo |
| NCT04075916 A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients | End Stage Renal Disease | P2 | Completed | 201 | Open-label | Epclusa |
| NCT01796470 Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P2 | Terminated | 66 | Open-label | Entospletinib, Idelalisib |
| NCT00002437 The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS | Cytomegalovirus Retinitis, HIV Infections | P2 | Completed | 48 | — | Cidofovir, Probenecid |
| NCT00507507 A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT) | Chronic Hepatitis B | P2 | Completed | 126 | RCT, Double-blind | Tenofovir DF, FTC, Placebo |
| NCT01356160 GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus | Hepatitis C, Chronic | P2 | Completed | 351 | RCT, Double-blind | GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo |
| NCT01452308 Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis | Liver Fibrosis | P2 | Completed | 20 | Open-label | Simtuzumab |
| NCT02579382 Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated | Chronic Hepatitis B | P2 | Completed | 192 | RCT, Double-blind | TDF, Vesatolimod, Placebo |
| NCT06046482 Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma | Head Neck, Squamous Cell Carcinoma of Head and Neck | P2 | Terminated | 4 | RCT, Open-label | Pembrolizumab, Magrolimab, cetuximab, Docetaxel |
| NCT04958785 Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | Triple-Negative Breast Cancer | P2 | Terminated | 92 | RCT, Open-label | Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy |
| NCT03207815 Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis | Noninfectious Uveitis | P2 | Terminated | 74 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib, Prednisone |
| NCT02348216 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | P1P2 | Completed | 307 | Open-label | Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone |
| NCT03036852 Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease | Chronic Hepatitis C | P2 | Completed | 59 | Open-label | SOF/VEL |
| NCT03312023 Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection | Hepatitis B | P2 | Completed | 21 | RCT, Open-label | Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG |
| NCT04539262 Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation | COVID-19 | P1P2 | Completed | 156 | RCT, Double-blind | Remdesivir (RDV), Placebo |
| NCT01479465 Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | Colorectal Cancer | P2 | Terminated | 266 | RCT, Double-blind | Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil |
| NCT03201445 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease | Inflammatory Bowel Disease | P2 | Terminated | 139 | RCT, Double-blind | Filgotinib, Placebo, Standard of Care |
| NCT00547066 Study of Veltuzumab (hA20) at Different Doses in Patients With ITP | Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura | P1P2 | Terminated | 48 | Open-label | veltuzumab |
| NCT01648205 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients | Long QT Syndrome | P2 | Completed | 25 | Double-blind | Placebo, Ranolazine |
| NCT01938430 Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant | Chronic HCV Infection | P2 | Completed | 339 | RCT, Open-label | LDV/SOF, RBV |
| NCT01146808 Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver | Hepatitis B, Liver Transplantation | P1P2 | Completed | 16 | Open-label | Adefovir dipivoxil and hepatitis B vaccination |
| NCT01672879 Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH | Liver Fibrosis Due to NASH | P2 | Terminated | 259 | RCT, Double-blind | Placebo, SIM |
| NCT04892446 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | P2 | Terminated | 36 | Open-label | Magrolimab, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib |
| NCT00445146 Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection | HIV Infections | P2 | Completed | 192 | Open-label | EVG, RTV, ARV regimen |
| NCT01799889 Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P2 | Terminated | 326 | RCT, Open-label | Entospletinib MM, Entospletinib SDD |
| NCT00664378 Efficacy Study of CYT997 in Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P2 | Terminated | 5 | Open-label | CYT997 |
| NCT01565850 D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults | Acquired Immunodeficiency Syndrome, HIV Infections | P2 | Completed | 153 | RCT, Double-blind | D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo |
| NCT02534350 Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection | Respiratory Syncytial Virus (RSV) | P2 | Completed | 61 | RCT, Double-blind | Presatovir, Placebo |
| NCT01101581 Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Non Hodgkin's Lymphoma, NHL | P1P2 | Withdrawn | — | RCT, Open-label | Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab |
| NCT00041639 Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | Pancreatic Neoplasms | P1P2 | Completed | 75 | Open-label | hMN14 (labetuzumab) |
| NCT03761056 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma | B-cell Lymphoma | P2 | Completed | 42 | Open-label | Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide |
| NCT02445131 Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) | Chronic Lymphocytic Leucemia | P2 | Completed | 48 | Open-label | Bendamustine, GA101, CAL-101 |
| NCT02378961 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection | Hepatitis C Virus Infection | P2 | Completed | 128 | Open-label | VOX, SOF/VEL |
| NCT03615066 Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment | Chronic Hepatitis B | P2 | Completed | 67 | RCT, Double-blind | Placebo, Selgantolimod, TAF |
| NCT00002234 Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | HIV Infections | P2 | Completed | 25 | — | Efavirenz, Adefovir dipivoxil, Lamivudine, Didanosine |
| NCT00907764 Stress Echocardiography Study With Regadenoson | Heart Disease, Coronary Artery Disease | P2 | Terminated | 22 | Open-label | regadenoson |
| NCT01336686 Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout | Hyperuricemia, Gout | P2 | Completed | 67 | RCT, Double-blind | Arhalofenate, Arhalofenate, Placebo comparator, Colchicine |
| NCT00148148 A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation | Hematopoietic Stem Cell Transplantation, Fungus Diseases | P2 | Completed | 75 | RCT, Open-label | caspofungin, liposomal amphotericin B |
| NCT01769196 Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | P2 | Terminated | 544 | RCT, Double-blind | Simtuzumab, Simtuzumab placebo |
| NCT05520723 Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED | Triple Negative Breast Cancer, Breast Cancer | P2 | Completed | 50 | Open-label | Sacituzumab govitecan, Loperamide, Granulocyte Colony-Stimulating Factor |
| NCT02010255 Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant | Chronic HCV Infection | P2 | Completed | 334 | RCT, Open-label | LDV/SOF, RBV |
| NCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Cutaneous Lupus Erythematosus (CLE) | P2 | Terminated | 20 | RCT, Double-blind | Edecesertib, Edecesertib Placebo |
| NCT01279707 Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | P1P2 | Unknown | 55 | Open-label | humanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab |
| NCT06071767 Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 | HIV-1-infection | P1P2 | SUSPENDED | 36 | RCT, Double-blind | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, MVA.tHIVconsv4, Placebo |
| NCT01522651 Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation | Atrial Fibrillation | P2 | Completed | 134 | RCT, Double-blind | Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo |
| NCT01826981 Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection | Chronic Hepatitis C | P2 | Completed | 359 | RCT, Open-label | LDV/SOF, SOF, RBV, Peg-IFN, GS-9669, VEL |
| NCT03100942 Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome | Sjogren's Syndrome | P2 | Completed | 152 | RCT, Double-blind | Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo |
| NCT01605890 Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients | HIV-2 Infection | P2 | Completed | 30 | Open-label | emtricitabine / tenofovir disoproxil fumarate / raltegravir . |
| NCT03987074 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | P2 | Completed | 109 | RCT, Open-label | Semaglutide, Firsocostat, Cilofexor |
| NCT00869557 Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV, HIV Infections | P2 | Completed | 71 | RCT, Double-blind | Stribild, Atripla |
| NCT02601313 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | Relapsed/Refractory Mantle Cell Lymphoma | P2 | Completed | 105 | Open-label | brexucabtagene autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel |
| NCT01672853 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis (PSC) | P2 | Completed | 235 | RCT, Double-blind | Simtuzumab, Placebo |
| NCT02166047 Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants | Chronic Hepatitis B | P2 | Completed | 162 | RCT, Double-blind | Vesatolimod, Placebo |
| NCT02759562 Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis | Cystic Fibrosis | P2 | Terminated | 6 | RCT, Double-blind | Andecaliximab, Placebo |
| NCT00002415 Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients | HIV Infections | P2 | Completed | 175 | Double-blind | Tenofovir disoproxil fumarate |
| NCT02781584 Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD) | P2 | Completed | 220 | Open-label | SEL, FIR, CILO, FENO, VAS |
| NCT05165771 Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment | Rheumatoid Arthritis | P2 | Withdrawn | — | RCT, Double-blind | GS-5718, GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg, Placebo to match Tofacitinib |
| NCT00422487 Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | P2 | Completed | 60 | RCT, Double-blind | MBX-2044, MBX-2044, MBX-2044, MBX-2044, MBX-2044, MBX-2044, Placebo for MBX-2044 |
| NCT05459571 Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | Relapsed or Refractory Large B-cell Lymphoma | P2 | Completed | 35 | Open-label | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone |
| NCT07743541 Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy | Uterine Endometrial Cancer | P1P2 | Not Yet Recruiting | 100 | Open-label | TUB-040 - Dose escalation, TUB-040 - RP2D |
| NCT03285711 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) | Lupus Membranous Nephropathy | P2 | Completed | 9 | RCT, Double-blind | Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo |
| NCT00334256 Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA) | HIV Infection, Pregnancy | P2 | Completed | 72 | Open-label | Tenofovir (TDF), Emtricitabine (FTC) |
| NCT00645294 Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV | Hepatitis B | P1P2 | Completed | 47 | RCT, Open-label | Adefovir dipivoxil, Adefovir Dipivoxil, Adefovir Dipivoxil |
| NCT00528060 Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada | HIV Infections | P2 | Completed | 35 | Open-label | Atazanavir, Ritonavir, Tenofovir/emtricitabine |
| NCT02161679 Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | Triple-negative Breast Cancer | P2 | Withdrawn | — | RCT, Open-label | IMMU-132 infusion is administered to participants in one arm for the study, IMMU-132 plus Carboplatin infusion |
| NCT00989586 Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Lymphoma | P1P2 | Completed | 35 | Open-label | milatuzumab, veltuzumab, veltuzumab and milatuzumab |
| NCT00499239 A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | P1P2 | Terminated | 32 | Open-label | GS-9219 |
| NCT04778410 Study of Magrolimab Combinations in Participants With Myeloid Malignancies | Myeloid Malignancies | P2 | Terminated | 54 | Open-label | Magrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486 |
| NCT01271790 A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | Hepatitis C, Chronic | P2 | Completed | 245 | RCT, Double-blind | Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, GS-9451, Tegobuvir placebo, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo, Pegasys®, Copegus® |
| NCT00421395 Safety Study of NHL With 90Y-hLL2 IgG | NHL, B-cell NHL | P1P2 | Completed | 59 | Open-label | 90Y-hLL2 |
| NCT00507689 Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant | Chronic Hepatitis B | P2 | Completed | 40 | RCT, Double-blind | FTC/TDF, Hepatitis B Immunoglobulin (HBIg) |
| NCT02994056 Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis | Hepatitis C Virus Infection | P2 | Completed | 32 | Open-label | SOF/VEL, RBV |
| NCT01497899 Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | Acquired Immunodeficiency Syndrome, HIV Infections | P2 | Completed | 279 | RCT, Double-blind | E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo |
| NCT03472950 Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis | ALS | P2 | Completed | 14 | Open-label | Ranolazine 500 MG, Ranolazine 1000 MG |
| NCT00002219 Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children | HIV Infections | P2 | Unknown | 36 | — | Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil |
| NCT06250036 Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer | Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer | P2 | SUSPENDED | 50 | RCT, Open-label | Single agent zimberelimab, Combination zimberelimab + domvanalimab |
| NCT01399008 Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients | Gout | P2 | Completed | 100 | RCT, Double-blind | Arhalofenate, Allopurinol, Colchicine, Placebo |
| NCT02568683 Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | Non-Hodgkin Lymphoma | P1P2 | Terminated | 10 | Open-label | Entospletinib, Vincristine |
| NCT05330429 Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | Metastatic Colorectal Cancer | P2 | Terminated | 77 | RCT, Open-label | Magrolimab, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin |
| NCT00002184 A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient | HIV Infections | P2 | Completed | 120 | Double-blind | Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine |
| NCT00701883 Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol | Hyperlipidemia | P2 | Completed | 183 | RCT, Double-blind | Placebo, MBX-8025, MBX-8025, Atorvastatin, MBX-8025, MBX-8025 |
| NCT01987453 Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study | HCV Infection | P2 | Completed | 100 | Open-label | LDV/SOF, RBV |
| NCT01282424 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | Follicular Lymphoma, Small Lymphocytic Lymphoma | P2 | Completed | 125 | Open-label | Idelalisib |
| NCT03491553 Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B | Chronic Hepatitis B | P2 | Completed | 48 | RCT, Double-blind | Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy |
| NCT00298363 Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease. | Chronic Hepatitis B | P2 | Completed | 112 | RCT, Double-blind | Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo |
| NCT00546793 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | NHL, Lymphoma, Non-Hodgkin | P1P2 | Completed | 32 | Open-label | veltuzumab |
| NCT02466516 Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 | Non-Alcoholic Steatohepatitis (NASH) | P2 | Completed | 72 | RCT, Open-label | SEL, SIM |
| NCT02226549 Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis | Hepatitis C Virus Infection | P2 | Completed | 47 | RCT, Open-label | LDV/SOF, VDV, RBV |
| NCT01559844 Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | Hepatitis C, Hepatocellular Carcinoma | P2 | Completed | 61 | Open-label | Sofosbuvir, Ribavirin |
| NCT02885181 Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate | Rheumatoid Arthritis | P2 | Completed | 83 | RCT, Double-blind | GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate |
| NCT00270556 Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART. | HIV | P2 | Completed | 100 | — | tenofovir disoproxil fumarate, Abacavir |
| NCT01687270 Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant | Recurrent Chronic Hepatitis C Virus, Post Liver Transplant | P2 | Completed | 40 | Open-label | Sofosbuvir, RBV |
| NCT00725803 Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV | HCV Infection | P2 | Completed | 33 | RCT, Double-blind | GS-9450, GS-9450 Placebo |
| NCT06123468 Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma | Esophagogastric Adenocarcinoma | P1P2 | Completed | 58 | Open-label | Sacituzumab govitecan |
| NCT00936715 Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States | Chronic Hepatitis B | P2 | Completed | 24 | Open-label | FTC/TDF |
| NCT06585150 Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection | RSV Infection | P2 | Terminated | 150 | RCT, Double-blind | Obeldesivir, Obeldesivir Placebo |
| NCT02862548 Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant | Chronic Hepatitis B | P2 | Completed | 51 | RCT, Open-label | TAF, TDF, Other approved antivirals |
| NCT01659047 A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P2 | Withdrawn | — | Open-label | GS-1101 |
| NCT01838434 Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Relapsed/Refractory Mantle Cell Lymphoma | P1 | Completed | 106 | RCT, Open-label | lenalidomide, idelalisib |
| NCT04087018 Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 18 | Open-label | zimberelimab |
| NCT05277012 A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants | Healthy Participants | P1 | Completed | 24 | RCT, Open-label | Etrumadenant |
| NCT03846310 A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer | P1 | Completed | 77 | Open-label | Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab |
| NCT05411146 A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | Healthy Participants | P1 | Completed | 8 | Open-label | [14C]-etrumadenant |
| NCT04314843 Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma | Relapsed/Refractory Large B-cell Lymphoma | P1 | Terminated | 6 | Open-label | Cyclophosphamide, Fludarabine, Lenzilumab, Axicabtagene Ciloleucel |
| NCT00561496 Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel | HIV Infections | P1 | Completed | 49 | Open-label | Tenofovir gel |
| NCT03628677 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Solid Tumor, Unspecified, Adult | P1 | Completed | 75 | Open-label | Domvanalimab, Zimberelimab |
| NCT04772989 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) | P1 | Completed | 94 | Open-label | AB308, Zimberelimab |
| NCT01779505 A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults | Healthy Volunteers | P1 | Completed | 60 | RCT, Open-label | GS-4774 |
| NCT01845740 Phase Ib Study of SC Milatuzumab in SLE | Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid | P1 | Completed | 22 | RCT, Double-blind | milatuzumab, Placebo |
| NCT01847391 A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects | Ischemic Heart Disease | P1 | Completed | 36 | RCT, Single-blind | GS-6615, Placebo |
| NCT00002396 The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients | HIV Infections | P1 | Unknown | 60 | Double-blind | Tenofovir disoproxil fumarate |
| NCT03135028 Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | Hematologic Malignancy, Acute Myeloid Leukemia | P1 | Terminated | 9 | Open-label | Entospletinib, Daunorubicin, Cytarabine |
| NCT02533427 Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol | HCV Infection | P1 | Completed | 15 | Open-label | SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol |
| NCT01675973 A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine | Severe Renal Impairment | P1 | Terminated | 4 | Open-label | RANEXA |
| NCT00041691 Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery | Colorectal Neoplasms | P1 | Terminated | 30 | Open-label | hMN14 (labetuzumab) |
| NCT01849003 Study of the Effect of GS-6615 in Subjects With LQT-3 | Long QT Syndrome | P1 | Completed | 24 | Open-label | GS-6615 |
| NCT02876796 Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | P1 | Completed | 30 | RCT, Double-blind | GS-0976, Placebo |
| NCT00185081 Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging | Colonic Neoplasms | P1 | Completed | 42 | Open-label | Indium labeled IMP-205xm734 |
| NCT04382404 Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir | Hepatitis C, Chronic | P1 | Completed | 11 | Open-label | Sofosbuvir-Velpatasvir Drug Combination |
| NCT02521376 Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function | Oncology | P1 | Completed | 56 | Open-label | Entospletinib |
| NCT02258555 Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | Follicular Lymphoma, Chronic Lymphocytic Leukemia | P1 | Terminated | 7 | Open-label | GS-9901 |
| NCT01740791 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection | Chronic Hepatitis C Virus | P1 | Completed | 103 | RCT, Double-blind | Velpatasvir, Placebo |
| NCT03399448 NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Multiple Myeloma, Melanoma | P1 | Terminated | 3 | Open-label | NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine |
| NCT01671787 A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B | Chronic Hepatitis B | P1 | Completed | 51 | RCT, Open-label | GS-7340, Tenofovir disoproxil fumarate |
| NCT01801293 A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806 | RSV Infection | P1 | Completed | 8 | Open-label | GS-5806 |
| NCT05770895 Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B | Chronic Hepatitis B | P1 | Completed | 83 | RCT, Double-blind | GS-2829, GS-6779, Placebo |
| NCT00710528 Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL) | P1 | Completed | 192 | Open-label | CAL-101 |
| NCT07530263 Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) | Chronic Pulmonary Aspergillosis | P1 | Not Yet Recruiting | 18 | RCT, Open-label | 12 mg of nebulised 99mTc-liposomal amphotericin B, 24 mg of nebulised 99mTc-liposomal amphotericin B |
| NCT01797419 Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) | Respiratory Syncytial Virus Infections | P1 | Withdrawn | — | RCT, Double-blind | GS-5806, Placebo |
| NCT01273402 Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Withdrawn | — | Open-label | TF2/IMP288 |
| NCT01590641 A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B | Hepatitis B, HBV | P1 | Completed | 49 | RCT, Double-blind | Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts |
| NCT02251457 Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 | Myotonia Congenita, Paramyotonia Congenita | P1 | Completed | 35 | Open-label | Ranolazine |
| NCT02002767 Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment | Hepatitis C Virus | P1 | Completed | 19 | Open-label | Velpatasvir |
| NCT03151057 Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia | P1 | Terminated | 16 | RCT, Double-blind | Idelalisib 100 MG, Placebo Oral Tablet |
| NCT02712346 The Role of Endothelin-1 in Sickle Cell Disease | Sickle Cell Anemia | P1 | Completed | 26 | RCT, Double-blind | Ambrisentan, Placebo |
| NCT00002346 The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients | HIV Infections | P1 | Completed | 36 | Double-blind | Adefovir dipivoxil |
| NCT01817985 A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment | Chronic Hepatitis C | P1 | Completed | 33 | Open-label | GS-5816 |
| NCT01840735 Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF | Cystic Fibrosis | P1 | Completed | 8 | RCT, Double-blind | GS-5737, Placebo |
| NCT01793649 A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects | Cystic Fibrosis, Chronic Obstructive Pulmonary Disease | P1 | Terminated | 7 | RCT, Double-blind | GS-5737 |
| NCT05458102 Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | P1 | Terminated | 18 | Open-label | Vesatolimod, Cobicistat, Voriconazole, Rifabutin |
| NCT04950764 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | Primary Biliary Cholangitis, Compensated Cirrhosis | P1 | Completed | 24 | Open-label | Seladelpar |
| NCT02365532 Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults | Long QT Syndrome | P1 | Completed | 60 | RCT, Double-blind | GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide |
| NCT00800579 Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers | Cystic Fibrosis | P1 | Completed | 12 | RCT, Double-blind | GS-9411, Placebo |
| NCT01816646 Intravesical Cidofovir for Hemorrhagic Cystitis | Blood And Marrow Transplantation | P1 | Completed | 6 | Open-label | Cidofovir, Probenecid |
| NCT03139370 Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | Solid Tumor | P1 | Terminated | 16 | Open-label | KITE-718, Cyclophosphamide, Fludarabine |
| NCT02185794 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection | Hepatitis C Virus Infection | P1 | Completed | 101 | RCT, Double-blind | Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL |
| NCT02402452 Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment | HCV Infection | P1 | Completed | 20 | Open-label | Voxilaprevir |
| NCT02397707 Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment | HCV Infection | P1 | Completed | 33 | Open-label | Voxilaprevir |
| NCT02296853 Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment | Hepatitis B Virus | P1 | Completed | 20 | Open-label | TAF |
| NCT00836914 Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber | Allergic Rhinitis | P1 | Completed | 41 | RCT, Double-blind | CAL-101, Placebo |
| NCT02392611 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | Solid Tumors and Lymphomas | P1 | Completed | 33 | Open-label | Alobresib, Exemestane, Fulvestrant |
| NCT02678338 CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | Acute Myeloid Leukemia, Myelodysplastic Syndrome | P1 | Completed | 20 | Open-label | Hu5F9-G4 |
| NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases | Systemic Lupus Erythematosus, Lupus Nephritis | P1 | By Invite | 52 | Open-label | KITE-363, Fludarabine, Cyclophosphamide |
| NCT00999531 A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers | Cystic Fibrosis, Mucociliary Clearance | P1 | Completed | 24 | RCT, Double-blind | GS-9411, Placebo |
| NCT02683005 Study of Hepatitis C Treatment During Pregnancy | Hepatitis C, Pregnancy | P1 | Completed | 9 | Open-label | ledipasvir/sofosbuvir |
| NCT02891408 Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function | Nonalcoholic Steatohepatitis (NASH) | P1 | Completed | 74 | Open-label | Firsocostat, Fenofibrate |
| NCT01705847 A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies | Lymphoid Malignancies | P1 | Completed | 39 | Open-label | GS-9820 |
| NCT03624036 Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma | P1 | Terminated | 16 | Open-label | brexucabtagene autoleucel, Fludarabine, Cyclophosphamide |
| NCT02203461 Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication | Insulin Resistance | P1 | Completed | 30 | RCT, Open-label | Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat, Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir, Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir |
| NCT02654002 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics | Nonalcoholic Steatohepatitis (NASH) | P1 | Completed | 120 | RCT, Double-blind | Cilofexor, Placebo |
| NCT01590654 A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection | Hepatitis B | P1 | Completed | 51 | RCT, Double-blind | Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620 |
| NCT02365506 Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome | LQT2 Syndrome | P1 | Completed | 13 | RCT, Double-blind | Eleclazine, Placebo |
| NCT02209987 Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults | Ulcerative Colitis | P1 | Completed | 28 | RCT, Open-label | GS-5745 SC, GS-5745 IV |
| NCT05169944 Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | Brain Cancer, Malignant Brain Tumor | P1 | Completed | 13 | Open-label | Magrolimab |
| NCT03405194 Same-Day Treatment With Genvoya vs. EFV/TDF/3TC | HIV/AIDS | N/A | Withdrawn | — | RCT, Open-label | Elvitegravir, Cobicistat, TAF, FTC, Efavirenz, TDF, and 3TC |
| NCT02619604 A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | N/A | Completed | 50 | Open-label | — |
| NCT03693040 Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP) | HIV Prevention | N/A | Unknown | 100 | Open-label | — |
| NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | Metastatic Non Small Cell Lung Cancer | Completed | 304 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT01236261 Prospective Population Study on Candidemia in Spain | Fungemia | Completed | 730 | — | — | |
| NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | Metastatic Nonsmall Cell Lung Cancer | Completed | 851 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial | Metastatic Breast Cancer | Completed | 724 | — | Palbociclib, Letrozole | |
| NCT02272062 Patient-Reported Preferences Affecting Revascularization Decisions | Coronary Artery Disease, Angina Pectoris | N/A | Completed | 203 | RCT, Double-blind | — |
| NCT04323761 Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | SARS-CoV2 Infection | APPROVED_FOR_MARKETING | — | — | Remdesivir | |
| NCT02907996 Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea | Hepatitis C Virus | Completed | 2,033 | — | Sofosbuvir | |
| NCT00263614 Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases. | Chronic Hepatitis B | Completed | 100 | — | — | |
| NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way | CD | N/A | Completed | 240 | Open-label | — |
| NCT03387397 Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities | HIV Infection Primary | Completed | 170 | — | — | |
| NCT01767597 Application of HBV Rapid Tests as a Tool for Wide-Use Screening | Hepatitis B, Liver Cirrhosis | N/A | Completed | 1,000 | RCT, Open-label | — |
| NCT04354818 Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA) | HIV-1-infection, Cancer | Unknown | 27 | — | — | |
| NCT03607396 Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis | Cystic Fibrosis | Unknown | 75 | — | — | |
| NCT01832571 SCOPE: Strategies to Combine PrEP With Prevention Efforts | HIV | N/A | Withdrawn | — | Open-label | Once daily Truvada® |
| NCT03752658 TAF Real World Study for Universal Effectiveness | Chronic Hepatitis b | Unknown | 500 | — | Tenofovir Alafenamide | |
| NCT00989807 Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis | Cystic Fibrosis, Pseudomonas Aeruginosa | APPROVED_FOR_MARKETING | — | — | Aztreonam lysine | |
| NCT02110914 A Coaching Intervention to Young Adults With Cystic Fibrosis | Cystic Fibrosis | N/A | Completed | 40 | RCT, Open-label | — |
| NCT02687061 Chronic Hepatitis B and C Recall Northern Holland | Hepatitis B, Hepatitis C | Unknown | 300 | — | — | |
| NCT01646541 Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery | Pulmonary Hypertension, Mitral Valve Disease | Completed | 100 | — | — | |
| NCT01072669 Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet | Ischemia | N/A | Completed | 20 | RCT, Double-blind | ambrisentan |
| NCT03986099 Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART | ART, HIV I Infection | N/A | Completed | 451 | Single-blind | — |
| NCT00158704 Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection. | Hepatitis B | N/A | Terminated | 400 | Open-label | Hepsera |
| NCT06688149 NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients | Non-alcoholic Fatty Liver Disease (NAFLD) | N/A | Completed | 536 | RCT, Open-label | — |
| NCT00905151 HIV and Kidney Function Study | HIV Infections, AIDS | Completed | 206 | — | — | |
| NCT03582098 Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | Chronic Lymphocytic Leukaemia | Completed | 112 | — | Idelalisib, Rituximab | |
| NCT02167100 Patient Retention in HIV Medical Care in a Primary Care Practice in Australia | HIV | Completed | 1,537 | — | — | |
| NCT04162756 Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies | Relapse/Refractory Mantle Cell Lymphoma | APPROVED_FOR_MARKETING | — | — | Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide | |
| NCT04891445 Hepatitis C in Severe Mental Disorders: Nursing Programme | Hepatitis C, Severe Mental Disorder | N/A | Completed | 16 | RCT, Single-blind | — |
| NCT02318524 Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients | COPD, Pulmonary Fungal Diseases | Completed | 65 | — | — | |
| NCT05520905 TelePrEP for At-risk Youth in Colorado | Hiv | N/A | Unknown | 100 | Open-label | — |
| NCT03195205 Identification to Elimination in HCV-Infected Individuals | Hepatitis C | Early P1 | Completed | 3,051 | Open-label | — |
| NCT03134105 A Wearable EducAtional Intervention to REduce Angina | Angina | N/A | Withdrawn | — | RCT, Open-label | — |
| NCT02562742 Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection | Hepatitis C | Completed | 554 | — | SOF, REB | |
| NCT02573376 Antiviral Pharmacology and Adherence in Drug Users | HEPATITIS C, Virus, Human Immunodeficiency | N/A | Completed | 73 | RCT, Open-label | — |
| NCT01326221 Single Dose Truvada in HIV-negative Men and Women | Pharmacokinetic Study in Healthy Volunteers | Completed | 12 | — | tenofovir + emtricitabine | |
| NCT01066858 Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding | HIV Infections | Completed | 1,765 | — | Tenofovir disoproxil fumarate (TDF) | |
| NCT02591277 Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection | Hepatitis C | Completed | 3,294 | — | Harvoni | |
| NCT04090151 The RESPOND Outcomes Study | HIV | Unknown | 37,853 | — | — | |
| NCT04582266 PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US | COVID-19 | Completed | 54 | — | Remdesivir | |
| NCT05526118 Advanced HIV: Outcomes for Rapid ART | HIV-1-infection | Unknown | 50 | — | Bictegravir/emtricitabine/tenofovir alafenamide | |
| NCT01779518 Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | — | — | Sofosbuvir, Ribavirin, Pegylated Interferon | |
| NCT00660361 A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients | HIV Infections, Hepatitis B Virus | Unknown | 92 | — | — | |
| NCT07618507 Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil | HIV, HIV -1 Infection | N/A | Completed | 777 | RCT, Open-label | TL+D antiretroviral |
| NCT02136511 Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia (CLL) | APPROVED_FOR_MARKETING | — | — | Idelalisib, Rituximab | |
| NCT04519970 Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) | Hiv | N/A | Completed | 100 | Open-label | — |
| NCT05776160 Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | Large B-cell Lymphoma, Follicular Lymphoma | AVAILABLE | — | — | Axicabtagene Ciloleucel | |
| NCT01093885 Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis | Systemic Sclerosis, Scleroderma | N/A | Completed | 15 | Open-label | Ambrisentan |
| NCT03794791 A Comprehensive HBsAg-positive Patients Centered Screening Strategy | Hepatitis B and Hepatitis C (Disorder) | Completed | 10,000 | — | — | |
| NCT03876470 Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia | Hepatitis C | Unknown | 300 | — | — | |
| NCT02928510 Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma | Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma | Terminated | 1 | — | Idelalisib | |
| NCT00499187 Fanconi Syndrome Due to ARVs in HIV-Infected Persons | HIV Infections, Fanconi Syndrome | Completed | 56 | — | — | |
| NCT04756193 Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound | Covid19, Echocardiography | Completed | 98 | — | — | |
| NCT02958358 FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan | Pulmonary Arterial Hypertension | N/A | Withdrawn | — | Open-label | — |
| NCT00002181 Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS | Herpes Simplex, HIV Infections | N/A | Completed | — | Open-label | Cidofovir |
| NCT05776134 Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia | AVAILABLE | — | — | Brexucabtagene Autoleucel | |
| NCT04009057 Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) | HIV-1-infection | Completed | 143 | — | — | |
| NCT05181956 Testing and Epidemiology of Delta Hepatitis | Chronic Hepatitis D Infection With Hepatitis B | Unknown | 5,000 | — | — | |
| NCT06465862 Development of a Silica Microparticle Taggant System to Measure ART Adherence | Hiv, Medication Adherence | N/A | Withdrawn | — | Open-label | Biktarvy Pill |
| NCT02592057 Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India | Hepatitis C Virus | Completed | 532 | — | SOF | |
| NCT00637429 HIV-HBV Co-Infection and Liver Disease | HIV Infections, HIV-HBV Co-Infection | Unknown | 70 | — | — | |
| NCT04930614 Prevalence and Risk Factors of HIV Infections in Transgender and Non-binary People in Flanders and Brussels (Belgium) | HIV Infections | Completed | 1,068 | — | — | |
| NCT04610762 HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels | Hepatitis C, Chronic | Completed | 103 | — | — | |
| NCT03627546 HCV Seek, Test and Rapid Treatment for Young PWID | Hepatitis C, Drug Use | N/A | Completed | 39 | RCT, Open-label | — |
| NCT03595527 Universal HIV Screening and Targeted HCV Screening in Emergency Department | Hepatitis C, Hiv | N/A | Completed | 6,350 | Open-label | — |
| NCT00002142 An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS | Cytomegalovirus Retinitis, HIV Infections | N/A | Completed | 100 | Open-label | Cidofovir, Probenecid |
| NCT02951364 Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea | Hepatitis C Virus | Completed | 1,081 | — | LDV/SOF | |
| NCT02427204 Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality | Hepatitis C Infection | Completed | 150 | — | — | |
| NCT01322932 Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey | HIV Infection | Completed | 95 | — | — | |
| NCT00002384 A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS | Cytomegalovirus Retinitis, HIV Infections | N/A | Unknown | — | — | Cidofovir |
| NCT00645736 CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study | Chronic Hepatitis B | Completed | 788 | — | — | |
| NCT03153462 Axicabtagene Ciloleucel Expanded Access Study | Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | APPROVED_FOR_MARKETING | — | — | Axicabtagene Ciloleucel | |
| NCT00002161 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3 | HIV Infections | N/A | Completed | 400 | Double-blind | Adefovir dipivoxil |
| NCT04847622 Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir. | Covid19 | Completed | 451 | — | Remdesivir | |
| NCT07385183 CARE: Comprehensive Assessment of Real-world Effectiveness of F/TAF in Persons Who Use Drugs (PWUD) | People Who Inject Drugs, PrEP Adherence | Not Yet Recruiting | 200 | — | — | |
| NCT06897059 Effectiveness of Smartphone Application for Adherence Support (Vuka+) | Adherence, Medication, Smartphone Application | N/A | Completed | 330 | RCT, Open-label | — |
| NCT03278990 Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves | HIV Prevention | N/A | Terminated | 26 | RCT, Double-blind | — |
| NCT01754428 Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age | Respiratory Syncytial Virus Infections | Completed | 2,432 | — | — | |
| NCT04226131 MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics | Rheumatoid Arthritis, Healthy Controls | N/A | Completed | 21 | Open-label | — |
| NCT03581383 Community Access, Retention in Care, and Engagement for Hepatitis C Treatment | Hepatitis C | N/A | Completed | 657 | RCT, Open-label | — |
| NCT01737047 The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty' | HIV Positive, Ageing | Completed | 1,377 | — | — | |
| NCT06539052 MIGrant Reflex Test HDV (MIGRED) Project | Hepatitis D Virus Infection | Not Yet Recruiting | 7,500 | — | — | |
| NCT01319253 A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies | Cystic Fibrosis, Pseudomonas Aeruginosa | Completed | 27 | — | — | |
| NCT03078153 Effect of Social Media Support and Financial Incentives on PrEP Adherence | Pre-Exposure Prophylaxis | N/A | Completed | 57 | RCT, Open-label | — |
| NCT05627466 US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | — | — | Magrolimab | |
| NCT07390409 ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa. | HIV | Not Yet Recruiting | 3,700 | — | Lenacapavir Injection, Cabotegravir (CAB) LA, Tenofovi-Emtricitabine (TDF/FTC) tablet | |
| NCT02342821 Empowering Immigrants in the Greater Boston Area to Connect to HBV Care | Hepatitis | Unknown | 100 | — | — | |
| NCT03038763 Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers | Hepatitis C, Hepatitis C, Chronic | Completed | 100 | — | — | |
| NCT05095818 Impact of Nursing Involvement on Implementation of HIV Prevention Services | Pre-Exposure Prophylaxis (PrEP) | N/A | Completed | 440 | RCT, Double-blind | — |